Condition
New Daily Persistent Headache (NDPH)
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 1 (1)
Trial Status
Completed2
Withdrawn1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05984719CompletedPrimary
New Daily Persistent Headache Survey
NCT05310227Not ApplicableWithdrawnPrimary
Nerivio Device for Treatment of New Daily Headache Persistence (NDHP)
NCT03447782Phase 1CompletedPrimary
Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children
NCT04260087Terminated
New Daily Persistent Headache Biomarkers Study
Showing all 4 trials